-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carfilzomib in Multiple Myeloma (Kahler Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfilzomib in Multiple Myeloma (Kahler Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfilzomib in Multiple Myeloma (Kahler Disease) Drug Details: Carfilzomib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Esophageal Cancer Drug Details: Donafenib tosylate (Zepsun)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Solid Tumor Drug Details: Donafenib tosylate (Zepsun)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Metastatic Melanoma Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Metastatic Pancreatic Cancer Drug Details: Niraparib (MK-4827, Zejula)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Metastatic Adenocarcinoma of The Pancreas Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Head And...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Pancreatic Cancer Drug Details: Donafenib tosylate (Zepsun) is a deuterated sorafenib derivative....
-
Product Insights
Liver Cirrhosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Liver Cirrhosis - Drugs In Development, 2023’, provides an overview of the Liver Cirrhosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Liver Cirrhosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Primary Biliary Cholangitis (Primary Biliary Cirrhosis) – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Biliary Cholangitis (Primary Biliary Cirrhosis) - Drugs In Development, 2023’, provides an overview of the Primary Biliary Cholangitis (Primary Biliary Cirrhosis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Biliary Cholangitis (Primary Biliary Cirrhosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...